Related Experiment Video
Updated: Apr 12, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.5K
Optimizing the use of neoadjuvant endocrine therapy
Laila S Agrawal1, Ingrid A Mayer
1Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Current Oncology Reports
|May 27, 2015
Summary
Neoadjuvant endocrine therapy is effective for estrogen receptor-positive breast cancer. However, overcoming endocrine therapy resistance is crucial for improving treatment strategies and discovering new therapeutic targets.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Neoadjuvant endocrine therapy is a standard approach for operable estrogen receptor-positive (ER+) breast cancer.
- Endocrine therapy resistance, both primary and acquired, presents a significant clinical challenge in breast cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of neoadjuvant endocrine therapy in ER+ breast cancer.
- To gain insights into the mechanisms of estrogen receptor-targeting agent efficacy and resistance.
- To identify novel molecular targets for future drug discovery and clinical investigation.
Main Methods:
- Clinical trials involving neoadjuvant endocrine therapy for ER+ breast cancer.
- Analysis of treatment response to guide chemotherapy decisions.
- Investigation of molecular mechanisms underlying endocrine therapy response and resistance.
Main Results:
- Neoadjuvant endocrine therapy trials help identify patients who can avoid chemotherapy.
- These trials provide a platform for understanding the biological basis of endocrine therapy effectiveness.
- Insights gained can inform strategies to overcome endocrine resistance.
Conclusions:
- Neoadjuvant endocrine therapy is a valuable strategy for ER+ breast cancer.
- Further research is needed to understand and counteract endocrine resistance.
- Identifying actionable molecular targets is key for advancing ER+ breast cancer treatment.
